Референции:

1. КХП Cosentyx, EMA 13.02.2025
2. Study Details | Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year | ClinicalTrials.gov
3. По НЗОК код и МКБ код на заболяването - Национална здравноосигурителна каса (НЗОК) (nhif.bg) 
4. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab long-term efficacy and safety in psoriasis: results through 5 years from the extension of the ERASURE and FIXTURE trials. British Journal of Dermatology. 2023;188(2):198-208.
5. Daudén E, García-Díez A, Puig L, et al. Secukinumab for Treatment of Plaque Psoriasis in Real-World Clinical Practice in Spain: Data from Biologic-Naïve and Biologic-Experienced Patients. Journal of Clinical Medicine. 2025;14(2):478.
6. Augustin M et al. European Academy of Dermatology and Venereology Congress. 17-20 September 2025; Paris, France. Poster P2083.
7. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis — results of two phase 3 trials. N Engl J Med. 2014;371:326-338.